The relationship between smoking, Raynaud's phenomenon, digital ulcers, and skin thickness in the Waikato Systemic Sclerosis cohort

被引:3
|
作者
Silva, Cherumi [1 ]
Solanki, Kamal K. [1 ]
White, Douglas H. N. [1 ]
机构
[1] Waikato Hosp, Rheumatol Dept, Pembroke St, Hamilton, New Zealand
来源
RHEUMATOLOGY AND IMMUNOLOGY RESEARCH | 2022年 / 3卷 / 02期
关键词
digital ulcers; Raynaud's; skin thickness; smoking; systemic; sclerosis; HEALTH-ASSESSMENT QUESTIONNAIRE; CIGARETTE-SMOKING; SCLERODERMA TRIALS; MANAGEMENT; CLASSIFICATION; PREVALENCE; MANIFESTATIONS; ANTIBODY; DISEASE; INDEX;
D O I
10.2478/rir-2022-0014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: Systemic sclerosis (SSc) is a heterogeneous complex autoimmune connective tissue disease with variable presentation as a consequence of multisystem involvement. One of the key features of SSc is Raynaud's phenomenon along with vascular endothelial dysfunction that leads to digital ulcers (DUs). Raynaud's tends to be triggered by decreasing thermal gradient exposure, while stress and smoking also play a role. DUs arising as a consequence of severe Raynaud's and vasculopathy are a major cause of morbidity and disability in SSc. We set out to determine the relationship between smoking, Raynaud's phenomenon, DUs, and skin thickness in our Waikato Systemic Sclerosis cohort. Methods: The Waikato Systemic Sclerosis (SSc) database was used to extract data. Variables collected included demographics, age of diagnosis, SSc subtypes, age at first non-Raynaud's phenomenon, medications used for treatment of Raynaud's phenomenon or ulcers, and maximal modified Rodnan skin score (mRSS). Raynaud's phenomenon and finger DUs (severity for each over the past week and since diagnosis) and a Scleroderma Health Assessment Questionnaire (SHAQ) visual analog 10 cm scale were collected. The lead rheumatologist completed a physician's assessment of Raynaud's and the disease severity questionnaire. Results: Of the cohort of 143 patients, 100 patients were eligible to complete the questionnaires. Seventy-five patients returned completed questionnaires. Of these, the majority were female (88%), 52 (69.3%) had limited cutaneous systemic sclerosis (lcSSc), 17 (22.7%) had diffuse cutaneous systemic sclerosis (dcSSc), and 6 (8%) had an overlap syndrome. Thirty-six (48%) had a smoking history (in the time frame of collection of serial data). Mean +/- standard deviation (SD) pack-years smoked were 17.11 +/- 15.29 years. Thirty-five participants had a history of DUs, with a median of 4 DU (range 1-20). Of 17 patients with dcSSc, 12 (70.6%) had ulcers in comparison with 17 of 52 (32.7%) patients with lcSSc. There was a significant relationship between SSc subtype and the number with ulcers (X-2 = 10.1, P = 0.007). There was also a significant relationship between physician severity of Raynaud's and presence of ulcers (t = 6.1, P < 0.001), which was not evident between patients' severity of Raynaud's and presence of ulcers (t = 1.9, P = 0.06). On the SHAQ score, smokers had significantly worse Raynaud's phenomenon over the prior week (t = 3.08, P = 0.03) and were more likely to note DUs over the preceding week, although the latter was not statistically significant (t = 1.95, P = 0.055). There was no association between smoking and skin thickness as measured by mRSS (r = 0.23, P = 0.19). Conclusion: Our study demonstrates that smokers have had worse Raynaud's phenomenon over the past week and they were also more likely to note DUs with a trend toward significance but not statistically significant most likely due to our small sample size. Our study also demonstrated that patients with dcSSc had more ulcers in comparison with lcSSc. This study justifies physicians strongly recommending smoking cessation in patients with SSc.
引用
收藏
页码:84 / 89
页数:6
相关论文
共 50 条
  • [21] Raynaud's Phenomenon with Focus on Systemic Sclerosis
    Maciejewska, Magdalena
    Sikora, Mariusz
    Maciejewski, Cezary
    Alda-Malicka, Rosanna
    Czuwara, Joanna
    Rudnicka, Lidia
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [22] RAYNAUD'S PHENOMENON AND SYSTEMIC SCLEROSIS: AN UPDATE
    Allanore, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 9 - 9
  • [23] Statins: A potentially useful therapeutic option in the management of systemic sclerosis-related raynaud's phenomenon and digital ulcers
    Abou-Raya, A.
    Abou-Raya, S.
    Helmii, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 103 - 103
  • [24] Early skin lesions of systemic sclerosis in comparison with primary Raynaud's phenomenon
    Nevskaya, T
    Radenska, S
    Guseva, N
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 343 - 344
  • [25] Systemic Sclerosis: Bilateral Improvement of Raynaud's Phenomenon with Unilateral Digital Sympathectomy
    Wasserman, Amy
    Brahn, Ernest
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 40 (02) : 137 - 146
  • [26] ACCESS TO TREATMENT FOR RAYNAUD'S PHENOMENON AND DIGITAL ULCERS FOR PATIENTS WITH SYSTEMIC SCLEROSIS DOESN'T FOLLOW EULAR/EUSTAR GUIDELINES
    Martin Calderon, L.
    Baron, M.
    Pope, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1237 - 1238
  • [27] The patient experience of Raynaud's phenomenon in systemic sclerosis
    Pauling, John D.
    Saketkoo, Lesley Ann
    Matucci-Cerinic, Marco
    Ingegnoli, Francesca
    Khanna, Dinesh
    RHEUMATOLOGY, 2019, 58 (01) : 18 - 26
  • [28] Raynaud's phenomenon and vascular disease in systemic sclerosis
    Generini, S
    Cerinic, MM
    RHEUMADERM: CURRENT ISSUES IN RHEUMATOLOGY AND DERMATOLOGY, 1999, 455 : 93 - 100
  • [29] HOW TO TREAT RAYNAUD'S PHENOMENON & SYSTEMIC SCLEROSIS?
    Riemekasten, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 4 - 4
  • [30] Treatment of Raynaud phenomenon and ischemic ulcers associated to systemic sclerosis with hyperbaric oxygen
    Ahijon-Lana, Maria
    Baragano-Ordonez, Elia
    Veiga-Cabello, Raul
    de la Cruz-Tapidor, Carmen
    Carreira, Patricia E.
    REUMATOLOGIA CLINICA, 2022, 18 (04): : 246 - 248